louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05389995: Potassium Citrate and Crystal Light Lemonade
Official title: Assessing the Effects of a Commercial Lemonade Beverage and Potassium Citrate on Urinary Stone Risk Factors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Kidney Stone
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2022-05-25
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To define the effect of crystal light, potassium citrate, or both on urinary stone risk factors in patients with a history of stone and hypocitraturia/low pH


Eligibility criteria: Inclusion Criteria:

1. Men and women between age 18-80 years
2. Willing to follow experimental protocol
3. Willing to complete 24-hour urine collections (three total)
4. Willing to sign the informed consent form
5. Completed Litholink Collection with blood work with results

   a. hypocitraturia OR aciduria i. Hypocitraturics must meet definition of \< 450 mg/day for men \< 550 mg/day for women.

   b. Low urine pH must be less than 5.6 c. potassium, BUN, creatinine, eGFR and hemoglobin A1c within normal limits

Exclusion Criteria:

1. Patients with severe hypocitraturia \< 200 mg/day (men or women)
2. Patients with hyperkalemia, uncontrolled diabetes, chronic kidney disease, adrenal insufficiency, delayed gastric emptying (or drug induced delayed gastric emptying), peptic ulcer disease, or active UTI
3. Patients with distal renal tubular acidosis or medication induced RTA (e.g. carbonic anhydrase inhibitor, topiramate)
4. Members of vulnerable patient populations
5. Allergies to ingredients in crystal light
6. Patients lacking decisional capacity

Primary outcomes:
measure: urine citrate levels
timeFrame: Day 7 of week 1
measure: urine citrate levels
timeFrame: Day 7 of week 3
measure: urine citrate levels
timeFrame: Day 7 of week 5
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
Study officials:
References:
Clinical trial NCT05032495: Patient Engagement Study to Evaluate the Use of Biological Therapies for Cardiac Arrhythmias
Official title: Patient Directed Strategies for Cardiac Arrhythmia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Arrythmia
Keywords: Patient engagement
Lead sponsor: Ottawa Heart Institute Research Corporation
Sponsor class: OTHER
First posted: 2021-09-02
Enrollment: 22
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will be recruited from in house databases after confirming patients have agreed to participate in research.

Brief summary: In this patient engagement study, patients and partners will attend a presentation, group meeting and responding to the survey to help the research team gage the acceptability of using a biological therapy to prevent cardiac arrhythmia. Patient Partners will also help to clarify which outcomes are important to patients, to ensure the selected outcomes align with patient interests.

Detailed description: There will be four study groups:

1. Heart patients who experienced a cardiac arrhythmia while in hospital,
2. Heart patients who did not experience a cardiac arrhythmia while in hospital,
3. Heart patients with an upcoming procedure that have not had a cardiac arrhythmia,
4. Members of the general public.

There will be a presentation, two surveys and a team meeting. Results will be compiled and analyzed.

Eligibility criteria: Inclusion criteria:

* Upcoming or previous cardiac procedure.

Exclusion Criteria:

* Inability to complete an electronic survey or participate in a small group meeting.

Primary outcomes:
measure: Number of participants that would accept a biological therapy for a cardiac arrhythmia as assessed using a survey
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: University of Ottawa Heart Insitute
state: Ontario
Study officials:
affiliation: Ottawa Heart Institute Research Corporation
name: Darryl Davis
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01140295: Bowel Preparation for Colonoscopy in Children
Official title: Polyethylene Glycol Powder Solution vs Senna for Bowel Preparation for Colonoscopy in Children: A Prospective, Randomized, Investigator-Blinded Trial.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Colonoscopy Preparation
Keywords: Preparation
Pediatric
Colonoscopy
Lead sponsor: Children's Hospital of Philadelphia
Sponsor class: OTHER
First posted: 2010-06-09
Enrollment: 33
Sex: ALL
Minimum age (years): 6
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The primary objective of this study is to determine whether Miralax results in a more efficacious preparation as compared to senna for pediatric colonoscopy.

Detailed description: Study subjects will be randomized in two groups: Group one will receive 1.5 g/kg of Miralax orally the day before procedure and one day of clear liquid diet, while subjects in Group 2 will receive two doses of senna the day before procedure with two days of liquid diet (one day full liquid and one day clear liquid diet). On the day of the procedure parents/subjects will complete a questionnaire regarding prep compliance and adverse events. Electrolytes will be obtained prior to colonoscopy to monitor for electrolyte imbalance. Endoscopists will assess preparation for colonoscopy using validated cleanliness scale (Aronchick scale).

Eligibility criteria: Inclusion Criteria:

1. Subjects age 6-21 yrs for senna, PEG-P groups
2. Subjects age 13-21 yrs for NaP group
3. First time colonoscopy
4. Patient weight \<70 kg for PEG-P group (to not exceed 51 grams/dose)

Exclusion Criteria:

1. Chronic renal, liver, or heart failure
2. Chronic constipation
3. Patients on the GI inpatient or consult service.
4. Subjects taking senna or PEG on a regular basis for laxative reasons.
5. Pregnant or lactating females

Primary outcomes:
measure: Efficacy of Colon Preparation
timeFrame: The outcome measure will be assessed once one day after the completion of colonoscopy preparation
Secondary outcomes:
measure: Proportion of Patients With Abnormal Electrolyte Levels
timeFrame: The outcome measure will be assessed once one day after the completion of colonoscopy preparation
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: The Children's Hospital of Philadelphia
state: Pennsylvania
Study officials:
affiliation: Children's Hospital of Philadelphia
name: Petar Mamula, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Terry NA, Chen-Lim ML, Ely E, Jatla M, Ciavardone D, Esch S, Farace L, Jannelli F, Puma A, Carlow D, Mamula P. Polyethylene glycol powder solution versus senna for bowel preparation for colonoscopy in children. J Pediatr Gastroenterol Nutr. 2013 Feb;56(2):215-9. doi: 10.1097/MPG.0b013e3182633d0a.
Clinical trial NCT00136695: Anastrozole Administration in Elderly Hypogonadal Men
Official title: Anastrozole Administration in Elderly Hypogonadal Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hypogonadism
Keywords: Aging
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: National Institute on Aging (NIA)
First posted: 2005-08-29
Enrollment: 88
Sex: MALE
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to assess the effects of sustained aromatase inhibitor therapy to reduce estrogen levels in elderly men with mild hypogonadism (a decreased level of sex hormones).

Detailed description: It has long been accepted that aging in men is associated with a slow, steady decline in gonadal androgen (male sex hormone) production. Several studies have explored androgen replacement, but the safety and efficacy of testosterone administration remains controversial. Aromatase inhibitors may provide a particularly useful way to restore normal androgen production in aging men.

This study will recruit 150 male volunteers, 60 years of age or older, to be randomized to receive either anastrozole or a placebo for 24 months. Six visits are planned over the 96-week treatment period.

Eligibility criteria: Inclusion Criteria:

* Men ages 60 and older
* Serum testosterone between 150-300 ng/dL
* Symptoms suggestive of androgen deficiency

Primary outcomes:
measure: Change in Lean Body Mass
timeFrame: Baseline and 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: General Clinical Research Center, Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Benjamin Z. Leder, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab. 2004 Mar;89(3):1174-80. doi: 10.1210/jc.2003-031467.
citation: Taxel P, Kennedy DG, Fall PM, Willard AK, Clive JM, Raisz LG. The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J Clin Endocrinol Metab. 2001 Jun;86(6):2869-74. doi: 10.1210/jcem.86.6.7541.
Clinical trial NCT06219395: Capsule Endoscopy in Iron Deficiency Anaemia
Official title: Diagnostic Yield of Video Capsule Endoscopy for Iron Deficiency Anaemia
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Iron Deficiency Anemia
Bowel Cancer
Lead sponsor: Vastra Gotaland Region
Sponsor class: OTHER_GOV
First posted: 2024-01-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Persons with Iron Deficiency Anaemia referred for endoscopic diagnostic work-up

Brief summary: This project aim to investigate whether wireless capsule endoscopy(WCE) has a similar diagnostic yield as conventional endoscopy in detecting the cause of iron deficiency anemia (IDA)

Detailed description: IDA is common and 90-95% of cases are caused by bleeding from ulcers, tumours or vascular malformations in the oesophagus, stomach, duodenum, small intestine or the large bowel.Bleeding from more than one localisation is common.

International guidelines recommend bidirectional endoscopy(gastro- and colonoscopy) to detect and treat the source of bleeding.

Our hypothesis is that WCE is non-inferior to the combination of gastroscopy and colonoscopy in locating GI-bleeding and that complete examinations will be achieved in ≥90% of the examinations.

Eligibility criteria: Inclusion Criteria:

* Referred to flexible endoscopy for a verified Iron Deficiency Anaemia

Exclusion Criteria:

* Unwillingness to participate
* Not able to provide informed consent
* Not understanding the instructions
* Severe cardio-vascular disease New York Heart Association III-IV
* Symptoms of bowel obstruction/previous bowel obstruction
* Bowel surgery except for end to end anastomosis in the colon
* Pregnancy

Primary outcomes:
measure: Diagnostic yield
timeFrame: 90 minutes
Secondary outcomes:
measure: Small bowel lesions
timeFrame: 90 minutes
measure: Complete examination
timeFrame: 90 minutes
measure: Bowel preparation
timeFrame: 90 minute
measure: Adequate examinations
timeFrame: 90 minutes
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Sahlgrenska University Hospital
Study officials:
affiliation: Sahlgrenska University Hospital
name: Thomas de Lange, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06665295: THRIVE-CAR-T Digital App
Official title: Randomized Controlled Trial of a Supportive Care Digital Application (THRIVE-CAR-T) for Patients Receiving CAR-T Cell Therapy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: CAR T-Cell Therapy
Keywords: car-t cell therapy
digital application
mobile application
randomized controlled trial
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2024-10-30
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this clinical trial is to learn if a digital mobile application called THRIVE-CAR-T is helpful for the care of patients undergoing CAR-T cell therapy. The main question\[s\] it aims to answer are whether the THRIVE-CAR-T app is feasible and acceptable to patients.

Detailed description: This pilot randomized controlled trial aims to examine the feasibility, acceptability, and preliminary effects of a supportive care digital app (THRIVE-CAR-T) versus usual care in patients receiving chimeric antigen receptor T-cell therapy (CAR-T). The primary objective of the study is to determine if THRIVE-CAR-T is feasible and acceptable to patients. The exploratory objective is to assess the preliminary effects of THRIVE-CAR-T for improving patient-reported quality of life (QOL), psychological distress, and self efficacy.

Eligibility criteria: Inclusion Criteria:

1. Age 18 years or older
2. Ability to understand English
3. Diagnosis of a hematologic malignancy
4. Receiving autologous CAR-T at MGH with an FDA approved cellular therapy product

Exclusion Criteria:

1. Impaired cognition or uncontrolled mental illness that prohibits the ability to provide informed consent based on the oncology clinician assessment
2. Already participating in another supportive care clinical trial

Primary outcomes:
measure: Feasibility
timeFrame: Through study completion, an average of 2 years
Secondary outcomes:
measure: Acceptability
timeFrame: Through study completion, an average of 2 years
measure: Quality of life
timeFrame: From enrollment until 90 days after CAR-T cell therapy
measure: Anxiety symptoms
timeFrame: From enrollment until 90 days after CAR-T cell therapy
measure: Depression symptoms
timeFrame: From enrollment until 90 days after CAR-T cell therapy
measure: PTSD symptoms
timeFrame: From enrollment until 90 days after CAR-T cell therapy
Other outcomes:
measure: Self-efficacy
timeFrame: From enrollment until 90 days after CAR-T cell therapy
measure: Coping
timeFrame: From enrollment until 90 days after CAR-T cell therapy
measure: Knowledge about CAR-T cell therapy
timeFrame: From enrollment until 90 days after CAR-T cell therapy
measure: Usability of THRIVE-CAR-T
timeFrame: From enrollment until 30 days after CAR-T cell therapy
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
References:
Clinical trial NCT00483795: Pilot Evaluation of Two Multipurpose Solutions in Regards to Corneal Staining
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Corneal Staining
Lead sponsor: Innovative Medical
Sponsor class: INDUSTRY
First posted: 2007-06-07
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: To evaluate corneal staining after contact lens instillation with two different multi purpose solutions.


Eligibility criteria: Inclusion Criteria:

* Patients 18 yrs or older
* Males or females
* Any race or ethnic background
* CL patients using (multipurpose solutions) MPS
* Patients using Acuvue 2 lenses

Exclusion Criteria:

* Corneal refractive surgery within 6 months of this study.
* Contact lens use on day of examination.
* Corneal ectasia.
* Current use of Restasis

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hazleton
country: United States
facility: Hazleton Eye Specialists
state: Pennsylvania
Study officials:
affiliation: Hazleton Eye Specialists
name: Thomas Kislan, OD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03233295: A Prospective, Single-centre, Open-label Study to Confirm the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency
Official title: A Prospective, Single-centre, Open-label Study to Confirm the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Vitamin D Deficiency
Lead sponsor: Kwang Dong Pharmaceutical co., ltd.
Sponsor class: INDUSTRY
First posted: 2017-07-28
Enrollment: 108
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A Prospective, Single-centre, Open-label Study to Confirm the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in adults with Vitamin D Deficiency


Eligibility criteria: Inclusion Criteria:

* Subjects with vitamin D deficiency

Exclusion Criteria:

* Subjects who experienced a hypersensitivity to the cholecalciferol
* Subjects with Hypercalcemia
* Subjects with Hypercalciuria
* Subjects with renal impairment
* Subjects with calcium stone
* Subjects diagnosed with sarcoidosis or pseudo-hypoparathyroidism
* Subjects who are to take vitamin D supplements during the study period

Primary outcomes:
measure: serum 25(OH)D concentration
timeFrame: 12 months
Secondary outcomes:
measure: serum 1,25(OH)2D concentration
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00449995: Confocal Laserscanning Microscopy for Detection of Barretts Esophagus
Official title: Confocal Laserscanning Microscopy for Detection of Barretts Esophagus. A Blinded Multi-Center Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Barrett Esophagus
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
Collaborators: name: Charite University, Berlin, Germany
name: Technische Universität Dresden
First posted: 2007-03-21
Enrollment: 73
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Four quadrant biopsies in regular ranges is the goldstandard in monitoring this disease. The ideal situation for the endoscopist is to visualize cellular structures, which implies having microscopic imaging available. A potential candidate to fill this gap could be confocal fluorescence microscopy (Cellvizio®-GI and Mauna Kea Technologies). To compare the gold standard with the confocal fluorescence microscopy for detection of metaplastic - or intraepithelial neoplastic changes of barrett-suspicious esophageal mucosa this study has been initiated.


Eligibility criteria: Inclusion Criteria:

* age between 18 and 80 years
* regular esophagogastroduodenoscopy for patients with known barrett esophagus (at least stadium C0M1)
* patients presenting for endoscopic mucosectomy with intraepithelial neoplastic changes \<1cm
* patients presenting with suspected intraepithelial neoplastic changes
* patients receiving acid suppressive therapy in standard dose for at least 4 weeks

Exclusion Criteria:

* no informed consent
* thrombocytopenia, quick \<50%, PTT \>50 sec
* patients with coronary heart disease or existent valve plasties
* women with potential pregnancy
* patients with chronic renal failure
* patients with allergies
* patients with chronic obstructive pulmonary disease

Primary outcomes:
measure: diagnostic accuracy of confocal laser scanning microscopy for detection of metaplasia or neoplasia in Barrett´s esophagus
Secondary outcomes:
measure: inter- and intra observer variability for confocal laser scanning microscopy
Other outcomes:
Locations:
city: Munich
country: Germany
facility: 2nd department of the Medical Clinic of the Technical University Munich
state: Bavaria
Study officials:
affiliation: Technical University Munich
name: Alexander Meining, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02308995: Barbed Sutures Versus Conventional Sutures in Laparoscopic Excision of Endometrioma
Official title: Barbed Sutures Versus Conventional Sutures in Laparoscopic Excision of Endometrioma . A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Endometriosis
Keywords: Endometriosis
Laparoscopy
Barbed sutures
Lead sponsor: Aljazeera Hospital
Sponsor class: OTHER
First posted: 2014-12-05
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this randomized controlled trial is to compare operative data and early postoperative outcomes of laparoscopic excision of endometrioma using barbed sutures with those of laparoscopic excision of endometrioma using conventional sutures.

Detailed description: Several authors reported the use of barbed sutures in myomectomy , hysterectomy and closure of vaginal vault. A recent meta-analysis comparing the efficacy of laparoscopic suturing using barbed suture or conventional sutures in myomectomy or hysterectomy revealed that suturing with barbed sutures was associated with less suturing time and operative time.

Although numerous studies revealed the advantages of using barbed sutures , no studies have yet evaluated the use of barbed sutures in laparoscopic excision of endometrioma.

The aim of this randomized controlled trial is to compare operative data and early postoperative outcomes of laparoscopic excision of endometrioma using barbed sutures with those of laparoscopic excision of endometrioma using conventional sutures.

Eligibility criteria: Inclusion Criteria:

* Unilateral endometrioma more than 3 cm in mean diameter

Exclusion Criteria:

* Bilateral endometriomata
* Conversion of laparoscopy to laparotomy
* Contraindications for general anesthesia

Primary outcomes:
measure: Suturing time of endometrioma bed
timeFrame: During cystectomy operation
Secondary outcomes:
measure: Operative time
timeFrame: During cystectomy operation
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Aljazeera hospital
Study officials:
affiliation: Aljazeera Hospital
name: Usama M Fouda, M.D,PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00434395: Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects
Official title: A Randomized, Double-Blind, Placebo- and Moxifloxacin (Open-Label)-Controlled, 4-Period Crossover Study of the Effects of a Single Dose of MOA-728 Infused Intravenously on Cardiac Repolarization in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Bausch Health Americas, Inc.
Sponsor class: INDUSTRY
First posted: 2007-02-13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to assess the effects of MOA-728 on cardiac repolarization in healthy subjects.


Eligibility criteria: Inclusion Criteria:

* Generally healthy subjects men or women aged 18-50

Exclusion Criteria:

* Any significant clinically important disease
* Family history of long QT syndrome and/or sudden cardiac death
* Allergy to moxifloxacin or the quinolone class of antibiotics

Primary outcomes:
measure: Cardiac repolarization will be assessed by the QTc interval in healthy subjects.
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
state: Arizona
Study officials:
affiliation: Bausch Health Americas, Inc.
name: Jeff Cohn
role: STUDY_DIRECTOR
References: